BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Pugh D, Karabayas M, Basu N, Cid MC, Goel R, Goodyear CS, Grayson PC, McAdoo SP, Mason JC, Owen C, Weyand CM, Youngstein T, Dhaun N. Large-vessel vasculitis. Nat Rev Dis Primers 2022;7:93. [PMID: 34992251 DOI: 10.1038/s41572-021-00327-5] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 9.0] [Reference Citation Analysis]
Number Citing Articles
1 Tawakol A, Osborne MT. Somatostatin Receptor 2-Targeted PET Radiotracers Shine in Assessing Inflammatory Activity in Large Vessel Vasculitis. J Am Coll Cardiol 2023;81:355-7. [PMID: 36697135 DOI: 10.1016/j.jacc.2022.10.035] [Reference Citation Analysis]
2 Nassarmadji K, Vanjak A, Bourdin V, Champion K, Burlacu R, Mouly S, Sène D, Comarmond C. 18-Fluorodeoxyglucose positron emission tomography/computed tomography for large vessel vasculitis in clinical practice. Front Med (Lausanne) 2023;10:1103752. [PMID: 36744139 DOI: 10.3389/fmed.2023.1103752] [Reference Citation Analysis]
3 Auanassova A, Yessirkepov M, Zimba O. The impact of the COVID-19 pandemic on patients with systemic vasculitis: a single-centre retrospective study. Rheumatol Int 2023;:1-8. [PMID: 36645477 DOI: 10.1007/s00296-023-05276-8] [Reference Citation Analysis]
4 Misra DP, Singh K, Rathore U, Patro P, Tomelleri A, Campochiaro C, Agarwal V, Sharma A. The effectiveness of tocilizumab and its comparison with tumor necrosis factor alpha inhibitors for Takayasu Arteritis: A systematic review and meta-analysis. Autoimmun Rev 2023;22:103275. [PMID: 36652977 DOI: 10.1016/j.autrev.2023.103275] [Reference Citation Analysis]
5 Suljič A, Hočevar A, Jurčić V, Bolha L. Evaluation of Arterial Histopathology and microRNA Expression That Underlie Ultrasonography Findings in Temporal Arteries of Patients with Giant Cell Arteritis. Int J Mol Sci 2023;24. [PMID: 36675088 DOI: 10.3390/ijms24021572] [Reference Citation Analysis]
6 Tarkin JM, Gopalan D. Multimodality imaging of large-vessel vasculitis. Heart 2023;109:232-40. [PMID: 36446545 DOI: 10.1136/heartjnl-2022-321113] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Dhaun N, Pugh D, Youngstein T. Percutaneous Intervention in Takayasu Arteritis: Potential Advantages of Procedural Perseverance. J Am Coll Cardiol 2023;81:65-7. [PMID: 36599611 DOI: 10.1016/j.jacc.2022.11.009] [Reference Citation Analysis]
8 Siefert J, Kaufmann J, Thiele F, Walter-Rittel T, Rogasch J, Biesen R, Burmester GR, Amthauer H, Schneider U, Furth C. Performance of Deauville Criteria in ([18F])FDG-PET/CT Diagnostics of Giant Cell Arteritis. Diagnostics (Basel) 2023;13. [PMID: 36611449 DOI: 10.3390/diagnostics13010157] [Reference Citation Analysis]
9 Ramon A, Greigert H, Ornetti P, Maillefert JF, Bonnotte B, Samson M. Predictive Factors of Giant Cell Arteritis in Polymyalgia Rheumatica Patients. J Clin Med 2022;11. [PMID: 36556036 DOI: 10.3390/jcm11247412] [Reference Citation Analysis]
10 Misra DP, Tomelleri A, Rathore U, Benanti G, Singh K, Behera MR, Jain N, Ora M, Bhadauria DS, Gambhir S, Kumar S, Baldissera E, Agarwal V, Campochiaro C, Dagna L. Impact of Geographic Location on Diagnosis and Initial Management of Takayasu Arteritis: A Tale of Two Cohorts from Italy and India. Diagnostics (Basel) 2022;12. [PMID: 36553110 DOI: 10.3390/diagnostics12123102] [Reference Citation Analysis]
11 Aymonnier K, Amsler J, Lamprecht P, Salama A, Witko‐sarsat V. The neutrophil: A key resourceful agent in immune‐mediated vasculitis. Immunological Reviews 2022. [DOI: 10.1111/imr.13170] [Reference Citation Analysis]
12 Misra DP, Rathore U, Mishra P, Singh K, Thakare DR, Behera MR, Jain N, Ora M, Bhadauria DS, Gambhir S, Kumar S, Agarwal V. Comparison of Presentation and Prognosis of Takayasu Arteritis with or without Stroke or Transient Ischemic Attack-A Retrospective Cohort Study. Life (Basel) 2022;12. [PMID: 36431038 DOI: 10.3390/life12111904] [Reference Citation Analysis]
13 Michailidou D, Zhang T, Kuderer NM, Lyman GH, Diamantopoulos AP, Stamatis P, Ng B. Predictive models for thromboembolic events in giant cell arteritis: A US veterans health administration population-based study. Front Immunol 2022;13:997347. [DOI: 10.3389/fimmu.2022.997347] [Reference Citation Analysis]
14 Henes JC, Saur S. Diagnostik und Therapie der Großgefäßvaskulitiden – Wo stehen wir aktuell? Aktuelle Rheumatologie 2022. [DOI: 10.1055/a-1931-3989] [Reference Citation Analysis]
15 Misra DP, Jain N, Ora M, Singh K, Agarwal V, Sharma A. Outcome Measures and Biomarkers for Disease Assessment in Takayasu Arteritis. Diagnostics (Basel) 2022;12:2565. [PMID: 36292253 DOI: 10.3390/diagnostics12102565] [Reference Citation Analysis]
16 Kiefer J, Mazzeffi M. Complications of Vascular Disease. Anesthesiology Clinics 2022. [DOI: 10.1016/j.anclin.2022.08.006] [Reference Citation Analysis]
17 Misra DP, Rathore U, Kopp CR, Patro P, Agarwal V, Sharma A. Presentation and clinical course of pediatric-onset versus adult-onset Takayasu arteritis-a systematic review and meta-analysis. Clin Rheumatol 2022. [PMID: 35927524 DOI: 10.1007/s10067-022-06318-5] [Reference Citation Analysis]
18 Rizzo C, La Barbera L, Miceli G, Tuttolomondo A, Guggino G. The innate face of Giant Cell Arteritis: Insight into cellular and molecular innate immunity pathways to unravel new possible biomarkers of disease. Front Mol Med 2022;2. [DOI: 10.3389/fmmed.2022.933161] [Reference Citation Analysis]
19 Grän F, Schilling B. Kutane Nebenwirkungen unter Immun-Checkpoint-Inhibitor-Therapie. Aktuelle Rheumatologie 2022;47:344-352. [DOI: 10.1055/a-1794-9687] [Reference Citation Analysis]
20 Shi H, Wu H, Winkler MA, Belin de Chantemèle EJ, Lee R, Kim HW, Weintraub NL. Perivascular adipose tissue in autoimmune rheumatic diseases. Pharmacol Res 2022;182:106354. [PMID: 35842184 DOI: 10.1016/j.phrs.2022.106354] [Reference Citation Analysis]
21 Aguiar MFD, Dantas JG, Bacchiega AB, Sachetto Z. Métricas nas vasculites sistêmicas. Rev Paul Reumatol 2022. [DOI: 10.46833/reumatologiasp.2022.21.2.59-71] [Reference Citation Analysis]
22 Watanabe R, Hashimoto M. Perspectives of JAK Inhibitors for Large Vessel Vasculitis. Front Immunol 2022;13:881705. [PMID: 35432355 DOI: 10.3389/fimmu.2022.881705] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
23 Samson M, Bonnotte B. Comment appliquer les recommandations EULAR et ACR pour le diagnostic et le traitement de l’artérite à cellules géantes ? La Revue de Médecine Interne 2022. [DOI: 10.1016/j.revmed.2022.02.004] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]